Evidence map›Paper›PMID 36411309›Full record

ArticleScientific reports2022

Comparative study of the cytotoxicity, apoptotic, and epigenetic effects of Boswellic acid derivatives on breast cancer.

Fatemeh Jamshidi-Adegani, Shokoofeh Ghaemi, Sulaiman Al-Hashmi, Saeid Vakilian, Juhaina Al-Kindi, Najeeb Ur Rehman, Khurshid Alam, Khamis Al-Riyami, Rene Csuk, Ehsan Arefian and 1 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.6field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 17 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. Phytochemical Screening and Biological Activities ofMolecules (Basel, Switzerland) · 2025
    Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 3 countries.

Fatemeh Jamshidi-AdeganiLaboratory for Stem Cell and Regenerative Medicine, Natural and Medical Sciences Research Center, University of Nizwa, P. O. Box: 33, 616, Nizwa, Oman.
Shokoofeh GhaemiLaboratory for Stem Cell and Regenerative Medicine, Natural and Medical Sciences Research Center, University of Nizwa, P. O. Box: 33, 616, Nizwa, Oman.
Sulaiman Al-HashmiLaboratory for Stem Cell and Regenerative Medicine, Natural and Medical Sciences Research Center, University of Nizwa, P. O. Box: 33, 616, Nizwa, Oman.
Saeid VakilianLaboratory for Stem Cell and Regenerative Medicine, Natural and Medical Sciences Research Center, University of Nizwa, P. O. Box: 33, 616, Nizwa, Oman.
Juhaina Al-KindiLaboratory for Stem Cell and Regenerative Medicine, Natural and Medical Sciences Research Center, University of Nizwa, P. O. Box: 33, 616, Nizwa, Oman.
Najeeb Ur RehmanNatural Products Laboratory, Natural and Medical Sciences Research Center, University of Nizwa, P. O. Box: 33, 616, Nizwa, Oman.
Khurshid AlamDepartment of Mechanical and Industrial Engineering, Sultan Qaboos University, 123, Muscat, Oman.
Khamis Al-RiyamiNatural Products Laboratory, Natural and Medical Sciences Research Center, University of Nizwa, P. O. Box: 33, 616, Nizwa, Oman.
Rene CsukOrganic Chemistry, Martin-Luther-University Halle-Wittenberg, Kurt-Mothes-Str. 2, 06120, Halle (Saale), Germany.
Ehsan ArefianDepartment of Microbiology, School of Biology, College of Science, University of Tehran, Tehran, Iran. arefian@ut.ac.ir.
Ahmed Al-HarrasiNatural Products Laboratory, Natural and Medical Sciences Research Center, University of Nizwa, P. O. Box: 33, 616, Nizwa, Oman. aharrasi@unizwa.edu.om.
University of Nizwa · OMMartin Luther University Halle-Wittenberg · DESultan Qaboos University · OMUniversity of Tehran · IR

Funding

The GCC co-funding CL/SQU-GCC/17/03The Research Council BFP/RGP/HSS/18/024
6 · The paper itself

Abstract

This study aimed to compare the effect of Boswellic acid derivatives on the viability, apoptosis, and epigenomic profiling of breast cancer. According to the viability assays, 3-O-acetyl-11-keto-β-Boswellic acid (AKBA) showed more toxicity against MDA-MB-231 cells when compared with the 3-O-acetyl-β-Boswellic acid (ABA). In contrast, ABA revealed less toxicity against MCF-10A. Cell cycle and apoptosis assays determined the maximum apoptotic effect of AKBA on MCF-7, and MDA-MB-231 cells. Interestingly, β-Boswellic acid (BA) and ABA did not promote the apoptosis in MCF-10A cells. Transwell migration assay indicated the greatest normalized inhibition (around 160%) in the migration of MDA-MB-231 cells induced by AKBA. The expression of P53, BAX, and BCL2 genes in cancerous cell lines has affirmed that both AKBA and ABA could induce the maximal apoptosis. Western-blot investigation demonstrated that the maximum over-expression of P53 protein (1.96 times) was caused by AKBA in MDA-MB-231 cells, followed by ABA in MCF-7 cells. The BCL2 protein expression was in agreement with the previously reported results. The global DNA methylation in both cancerous cells was reduced by ABA. These results suggest that ABA represented more epigenetic modulatory effect while AKBA shows more cytotoxic and apoptotic effect against breast cancer cell lines.

Indexed as

EpigenomicsNeoplasmsEpigenesis, GeneticProto-Oncogene Proteins c-bcl-2TriterpenesTumor Suppressor Protein p53acetyl-11-ketoboswellic acidboswellic acidProto-Oncogene Proteins c-bcl-2TriterpenesTumor Suppressor Protein p53

Identifiers

PMID36411309
PMCPMC9678894
OpenAlexW4309666437

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.